Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

NCT03193918

Esophagogastric Adenocarcinoma

COMPLETED PHASE1

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

NCT06690281

Gastrointestinal Carcinoma Pancreatic Cancer Hepatocellular Cancer +5 more

WITHDRAWN PHASE2

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

NCT04110093

Colorectal Cancer Immunotherapy

UNKNOWN PHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

NCT04854434

Metastatic Colorectal Cancer

TERMINATED PHASE2

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

NCT00483080

Colorectal Cancer (CRC)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Crenolanib (CP-868,596) is an orally bioavailable, selective inhibitor of PDGFR receptor tyrosine kinase with IC50s of 0.4 ng/mL and 0.8 ng/mL for PDGFRα and PDGFRβ, respectively.

In preclinical models of cell lines with the D842V mutation in the PDGFRA gene, crenolanib (CP-868,596) blocked phosphorylation of PDGFRα at nanomolar concentrations, suggesting that it may provide a clinical benefit to patients with D842V mutant GIST.

In addition, crenolanib was also active in inhibiting phosphorylation of cell lines with two point mutations (double mutants) PDGFRA V561D + D842V and PDGFRA T674I + D842V.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

D842-related Mutant GIST

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crenolanib (CP-868,596)

Group Type EXPERIMENTAL

Crenolanib besylate (CP-868,596-26), Dose: 140mg BID

Intervention Type DRUG

Highly potent inhibitor of both PDGFR receptors alpha and beta

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Crenolanib besylate (CP-868,596-26), Dose: 140mg BID

Highly potent inhibitor of both PDGFR receptors alpha and beta

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, of any racial or ethnic group
* Age 18 years or older
* Life expectancy of greater than 12 weeks
* Patient able and willing to provide informed consent
* Normal liver function, defined as AST and ALT ≤2.5x ULN, and Total Bilirubin ≤ 2x ULN.
* Total creatinine ≤ 1.5x ULN
* ECOG Performance Status 0 - 2 (Appendix II)
* Patients must have histologically or cytologically confirmed GIST with a D842-related mutation or deletion on the PDGFRA gene
* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>20 mm with conventional techniques or as \>10 mm with spiral CT scan. See Section 10.1.2 for the evaluation of measurable disease.
* Patients must have recovered from any prior therapy and completed the minimum of, either 5 half-lives of prior therapy or 2 weeks must have elapsed since prior treatment

Exclusion Criteria

* Patient unable to provide informed consent
* ECOG Performance status \> 2
* Any concurrent anticancer therapy, immunotherapy, or hormonal therapy.
* Any other investigational agents taken within 2 weeks of start of study drug or if study drug will commence within 5 half-lives of prior therapy
* Patients with known or active Hepatitis B or C; liver cirrhosis.
* Patients with active fungal, viral, and bacterial infections
* Positive serum pregnancy test
* Pregnant or lactating women
* Patients on concomitant medications that induce or inhibit CYP3A4 (Appendix III)
* Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No